7 Interactions found for:
Drug Interactions
Major
Oxycodone
+ Flexeril
The following applies to the ingredients: Oxycodone and Cyclobenzaprine (found in Flexeril)
Using narcotic pain or cough medications together with other medications that also cause central nervous system depression can lead to serious side effects including profound sedation, respiratory distress, coma, and even death. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. Do not drink alcohol or self-medicate with these medications without your doctor's approval, and do not exceed the doses or frequency and duration of use prescribed by your doctor. Also, because these medications may cause dizziness, drowsiness, difficulty concentrating, and impairment in judgment, reaction speed and motor coordination, you should avoid driving or operating hazardous machinery until you know how they affect you. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and Food Interactions
Major
Oxycodone
+ Food
The following applies to the ingredients: Oxycodone
Do not use alcohol or medications that contain alcohol while you are receiving treatment with oxyCODONE. This may increase nervous system side effects such as drowsiness, dizziness, lightheadedness, difficulty concentrating, and impairment in thinking and judgment. In severe cases, low blood pressure, respiratory distress, fainting, coma, or even death may occur. You may also want to avoid or limit the consumption of grapefruit and grapefruit juice, which can significantly increase the blood levels of oxycodone in some people. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. Do not use more than the recommended dose of oxyCODONE, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medication without first talking to your doctor.
The following applies to the ingredients: Oxycodone
Do not use ethanol while you are receiving treatment with oxyCODONE. This may increase nervous system side effects such as drowsiness, dizziness, lightheadedness, difficulty concentrating, and impairment in thinking and judgment. In severe cases, low blood pressure, respiratory distress, fainting, coma, or even death may occur. Talk to your doctor or pharmacist if you have questions on how to take this or other medications you are prescribed. Do not use more than the recommended dose of oxyCODONE and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medication without first talking to your doctor.
Moderate
Flexeril
+ Food
The following applies to the ingredients: Cyclobenzaprine (found in Flexeril)
Alcohol can increase the nervous system side effects of cyclobenzaprine such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with cyclobenzaprine. Do not use more than the recommended dose of cyclobenzaprine, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have any questions or concerns.
Drug and Pregnancy Interactions
Major
Oxycodone
+ Pregnancy
The following applies to the ingredients: Oxycodone
Professional Content
Use is not recommended.
-Some authorities recommend avoiding use, unless it is clearly needed.
AU TGA pregnancy category: C
US FDA pregnancy category: Not Assigned
Risk Summary: Based on animal data, may cause fetal harm; prolonged maternal use of opioids during pregnancy may cause neonatal opioid withdrawal syndrome.
Comments:
-Prolonged use of opioids during pregnancy can result in physical dependence in the neonate; women should be advised of the risk of neonatal abstinence syndrome and ensure that appropriate treatment will be available.
-Opioid analgesics, can prolong labor by temporarily reducing the strength, duration, and frequency of uterine contractions. These agents are not recommended during or immediately prior to labor.
-Monitor neonates exposed to opioid analgesics for signs of excess sedation and respiratory depression.
Opioid analgesics cross the placenta. The use of this drug during labor may cause respiratory depression in the newborn infant. Prolonged use of opioids during pregnancy can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. The onset, duration, and severity of the condition will vary based on use (duration of use, timing, and amount of last maternal use) and rate of elimination in the newborn. There are no controlled data in human pregnancy.
Chronic use of opioids may cause reduced fertility; it is unknown whether these effects are reversible.
AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details.
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.
References
- "Product Information. Percocet (acetaminophen-oxycodone)." DuPont Pharmaceuticals PROD (2001):
- "Product Information. Tylox (acetaminophen-oxycodone)." McNeil Pharmaceutical PROD (2001):
- "Product Information. OxyContin (oxycodone)." Purdue Frederick Company PROD (2001):
- Koren G, Pastuszak A, Ito S "Drugs in pregnancy." N Engl J Med 338 (1998): 1128-37
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Xtampza ER (oxyCODONE)." Patheon SUPPL-21 (2023):
Minor
Flexeril
+ Pregnancy
The following applies to the ingredients: Cyclobenzaprine (found in Flexeril)
Professional Content
This drug should be used during pregnancy only if clearly needed.
US FDA pregnancy category: B
Embryofetal development in rats and rabbits given approximately 3 and 15 times, respectively, the maximum recommended human dose (MRHD) was not adversely effected. Dams receiving this drug at doses 3 times or more the MRHD during pregnancy and lactation, had pups with decreased body weight and survival. There are no adequate and controlled studies in pregnant women.
US FDA pregnancy category B: Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.
adversely
References
- "Product Information. Flexeril (cyclobenzaprine)." Merck & Co., Inc PROD (2001):
- "Product Information. Amrix (cyclobenzaprine)." A-S Medication Solutions (2016):
Drug and Breastfeeding Interactions
Major
Oxycodone
+ Breastfeeding
The following applies to the ingredients: Oxycodone
Professional Content
Avoid during breastfeeding.
Excreted into human milk: Yes
Comments:
-Maternal use of oral opioids during breastfeeding can cause excess sedation and respiratory depression in the infant. In some cases, it may progress to rare but severe central nervous system depression.
-In breastfeeding patients, it is best to provide pain control with a nonnarcotic analgesic and limit maternal intake of this drug.
-If used, monitor breastfed infants closely for excess sedation, adequate weight gain, and respiratory depression.
-Withdrawal symptoms may occur in breastfed infants when maternal administration of an opioid is stopped or when breast-feeding is stopped.
Maternal use of opioids during breastfeeding can cause infant drowsiness, central nervous system depression, and even death. Infant sedation is common with maternal use of this drug. Newborn infants are particularly sensitive to the effects of even small dosages of opioid analgesics. When possible, pain control should be with a non opioid analgesic. However, if needed, use should be limited to the immediate-release products with a maximum dosage of 30 mg per day. Infants should be monitored closely for drowsiness, adequate weight gain, and developmental milestones, especially younger, exclusively breastfed infants.
References
- "Product Information. Percocet (acetaminophen-oxycodone)." DuPont Pharmaceuticals PROD (2001):
- "Product Information. Tylox (acetaminophen-oxycodone)." McNeil Pharmaceutical PROD (2001):
- "Product Information. OxyContin (oxycodone)." Purdue Frederick Company PROD (2001):
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- United States National Library of Medicine "Toxnet. Toxicology Data Network. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT" (2013):
- "Product Information. Xtampza ER (oxyCODONE)." Patheon SUPPL-21 (2023):
Minor
Flexeril
+ Breastfeeding
The following applies to the ingredients: Cyclobenzaprine (found in Flexeril)
Professional Content
Caution is recommended.
Excreted into human milk: Unknown
Excreted into animal milk: Yes
The effects in the nursing infant are unknown.
This drug has been shown to be excreted in rat milk and achieve concentrations in the milk which are 50% of those in the rat maternal plasma. As this drug is closely related to the tricyclic antidepressants, some of which are known to be excreted in human milk, use caution especially when other drugs that cause sedation are used simultaneously.
References
- Hucker HB, Stauffer SC, Balletto AJ, White SD, Zacchei AG, Arison BH "Physiological disposition and metabolism of cyclobenzaprine in the rat, dog, rhesus monkey, and man." Drug Metab Dispos 6 (1978): 659-72
- "Product Information. Flexeril (cyclobenzaprine)." Merck & Co., Inc PROD (2001):
- "Product Information. Amrix (cyclobenzaprine)." A-S Medication Solutions (2016):
Therapeutic Duplication Warnings
No warnings were found for your selected drugs.Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Switch to: Professional Interactions
| Drug Interaction Classification | |
|---|---|
These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication. |
|
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
| Unknown | No interaction information available. |
Disclaimer: This content should not be considered complete and should not be used in place of a call or visit to a healthcare professional. Use of this content is subject to our terms of use & medical disclaimer.